Biovie is trading 5.43% up at $1.69 before the September 28, 2026 session, rebounding from the September 25 close of $1.60 after several sessions near $1.60–$1.63. - The supplied price context follows a sharp September 18 decline. - BioVie’s investor-relations page lists no announcement dated September 25 or later; its latest release is the September 15 Phase 2 ADDRESS-LC results. - No clear new company-specific catalyst was identified; broader futures are lower, so the supplied market direction does not explain the move.